Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial

BACKGROUND: Cetuximab can reverse chemotherapy resistance in colorectal cancer. This study evaluated the efficacy and safety of the combination of docetaxel and cetuximab as a second-line treatment in docetaxel-refractory oesophagogastric cancer. METHODS: Patients received docetaxel 30 mg m(−2) on d...

Descripción completa

Detalles Bibliográficos
Autores principales: Tebbutt, N C, Parry, M M, Zannino, D, Strickland, A H, Van Hazel, G A, Pavlakis, N, Ganju, V, Mellor, D, Dobrovic, A, Gebski, V J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590676/
https://www.ncbi.nlm.nih.gov/pubmed/23412099
http://dx.doi.org/10.1038/bjc.2013.41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590676/
https://www.ncbi.nlm.nih.gov/pubmed/23412099
http://dx.doi.org/10.1038/bjc.2013.41

Ejemplares similares